.svg)
%201.svg){kind=icon}
The Role of AI-Ready Data in Multi-Modal Analysis and Decision-Making
%20(1).svg){kind=avatar}
January 11, 2025
In biopharma and healthcare research, the abundance of artificial intelligence (AI) algorithms and growing computing power has brought disruption to the industry. This led to an increase in multi-modal data and the analysis of this data can reveal insights that were previously unimaginable. Integrating these diverse data types into a cohesive, actionable format is a major bottleneck in biopharma and clinical research. Every type of data comes with its set of challenges, for example, clinical data is mostly unstructured, omics data tends to be massive and complex, and imaging data requires specialized processing. To add to this complexity, we face issues like inconsistent formats, missing metadata, and the need to ensure data interoperability. These challenges slow down the journey from data to insights, making it difficult to leverage the full potential of multi-modal analysis.
This is where Elucidata steps in.
Elucidata takes in raw, messy datasets and converts them into structured, AI-ready data. Using its proprietary tools and workflows, we ensure that data is clean, harmonized, and primed for machine learning applications. This helps researchers and decision-makers get data insights faster and make the right decisions to accelerate research.
Elucidata's platform, Polly, offers a comprehensive suite of features designed to streamline data ingestion, harmonization, and analysis. With modules dedicated to centralized data ingestion, multi-modal data harmonization, and a structured repository for data storage, Polly makes sure that complex biomedical data is organized into a user-friendly structure, enabling effortless exploration and analysis across multiple levels.
In this blog, we’ll explore why and how AI-ready data is important for multi-modal analysis and helps with smarter, faster, and more accurate decision-making in biopharma and healthcare.
Data builds the foundation of artificial intelligence and decides how well an AI will function. Without clean, well-structured, and accurate data, AI will produce unreliable and biased results. Therefore, ensuring that data is AI-ready sets the stage for accurate analysis.
AI-ready data is important for scalable, precise, and impactful multi-modal analysis. The diverse set of clinical, omics, and imaging data collected from different sources and available in different formats need to be harmonized and structured for integration into machine learning workflows.
The diversity of data and collection methods make the data that we use for multi-modal analysis of poor quality. The traditional methods used for data extraction, cleaning, and standardization are manual and prone to errors, leading to inefficiencies. In addition, metadata across repositories is mostly fragmented and inconsistent, making it complicated to create a unified dataset. Moreover, missing data and class imbalances skew results, and eventually, all of this affects the reliability of predictive models.
Now, the risks associated with low-quality data are significant. Models trained on unclean or incomplete datasets can produce biased or misleading insights, resulting in flawed conclusions and potentially costly missteps in decision-making. For example, in drug development, inaccurate data could lead to the selection of ineffective candidates for clinical trials, wasting time and resources. Moreover, in clinical diagnostics, faulty data can result in incorrect diagnoses, directly affecting patient care.
AI-ready data mitigates these risks by ensuring data integrity, consistency, and interoperability. It enables researchers and organizations to make confident, data-driven decisions that improve outcomes and accelerate innovation. By investing in the right tools and strategies, multi-modal analysis can significantly accelerate research on personalized treatment strategies, predictive diagnostics, and efficient drug discovery pipelines. Furthermore, robust data quality ensures regulatory compliance, which is critical in healthcare and biopharma industries.
Processing multi-modal data comes with its own set of challenges due to the inherent variability in data types and formats. Electronic health records (EHRs), genomics, imaging, and clinical trial data all require specialized approaches for extraction, cleaning, and analysis. Each data type presents unique complexities, making integration a resource-intensive task.
One significant hurdle is the inconsistency in metadata annotation and terminology across different sources. For instance, the same clinical condition might be recorded using varied terms such as “hyperglycemia” or “high blood sugar,” complicating data harmonization. This lack of standardization often leads to difficulties in aligning datasets, resulting in lost insights or duplication of effort. Metadata enrichment and curation processes are essential to address these gaps and ensure uniformity.
Interoperability is another critical issue. Most datasets are siloed in formats that don’t easily interact with one another, requiring significant time and effort to ensure seamless integration. For example, imaging data often uses DICOM formats, while omics data is stored in text-heavy formats like FASTQ or BAM. Harmonizing these disparate formats demands sophisticated pipelines and tools. Additionally, bridging these gaps often requires domain expertise, further increasing resource requirements.
Cleaning and transforming unstructured data into usable formats often involve labor-intensive workflows that slow down the analysis pipeline. Consider a scenario where genomics data contains incomplete sequences or imaging data has inconsistent annotations. Each of these issues requires meticulous attention to detail to resolve. Automated pipelines for cleaning and transformation are essential to ensure scalability and efficiency.
Data security, access control, and governance add yet another layer of complexity. Sensitive clinical and observational data require stringent protocols to ensure compliance with regulations like GDPR or HIPAA while maintaining usability. Balancing data accessibility with privacy and security is a challenge that organizations must continuously address. Furthermore, with increasing emphasis on data sovereignty, ensuring local compliance across global datasets has become critical.
Overcoming these challenges requires a robust framework that emphasizes standardization, automation, and secure data handling. Addressing these obstacles is key to unlocking the full potential of multi-modal data. Tools that prioritize these factors are critical in enabling researchers to work efficiently and confidently. Organizations must also foster cross-functional collaboration between data engineers, scientists, and clinicians to streamline workflows.
Elucidata’s AI-ready data platform is designed to tackle the complexities of multi-modal data processing, ensuring seamless ingestion, harmonization, and integration. Its suite of tools can help researchers and organizations efficiently process and convert their raw data into AI-ready data.
Seamlessly ingest data from S3, Blob, Drive, Box, or any cloud storage provider. Ensure data quality through comprehensive profiling and pre-harmonization QC reports that evaluate completeness, consistency, and accuracy. The platform generates unstructured data products that are easily findable, with role-based access control and version control for streamlined management.
Polly’s Harmonization Engine transforms raw, unstructured data by cleaning, harmonizing, and standardizing it to make it AI-ready. Using LLM-based models and scalable pipelines, the engine automates data processing and vocabulary mapping, producing standardized data products at a cost 4X lower than industry benchmarks.
Harmonized data is stored in PostGRES or Snowflake tables using standardized vocabularies alongside source values and codes. Elucidata’s proprietary data model, built on the OHDSI vocabulary, serves as a centralized ontology management system, ensuring consistent interpretation of clinical concepts across datasets.
Create custom dashboards for multi-modal data and AI-assisted cohort builders to generate insights without coding. These shareable, reusable tools across different Atlases leverage LLM-powered data retrieval, bioinformatics tools, and visualization features to accelerate predictions and insights from complex multi-modal datasets.
Elucidata’s proprietary software, Polly offers significant advantages for biopharma and healthcare organizations.
The platform enables faster integration of diverse data types, significantly reducing discovery timelines. Researchers can focus on generating insights rather than spending time on data preparation. For instance, in oncology research, harmonized datasets allow for the rapid identification of biomarkers that are critical for targeted therapies. Time savings translate directly into competitive advantages in fast-moving fields like personalized medicine.
Elucidata’s streamlined pipelines are designed to handle large and growing data volumes without requiring extensive manual intervention. This scalability ensures that organizations can keep pace with the increasing complexity of their data. For example, global clinical trials generating terabytes of data can be processed efficiently, enabling quicker results. Furthermore, the platform’s modular design allows users to scale specific functionalities as needed.
By delivering high-quality datasets, the platform minimizes errors in downstream processes. Reliable and consistent data enhances the performance of AI models, ensuring trustworthy outcomes in predictive modeling and decision-making. For example, accurate patient stratification models can lead to more effective clinical trials. Enhanced accuracy also ensures reproducibility, a key requirement in scientific research.
Automated workflows reduce time and resource demands, allowing teams to reallocate efforts toward strategic, value-added tasks. The cost savings achieved are particularly impactful in resource-intensive industries like biopharma, where data preparation often consumes a significant portion of the budget. Additionally, reducing manual intervention minimizes the risk of human error, further enhancing cost efficiency.
Elucidata helps organizations to use AI for predictive modeling, cohort identification, and data-driven decision-making. This capability drives innovation, enabling smarter approaches to drug discovery, personalized medicine, and clinical research. For example, AI models trained on harmonized datasets can predict patient responses to treatments, enhancing the personalization of care.
By harnessing structured and harmonized data from extensive genomics, treatment, and observational datasets, AI-ready data enables accurate identification of patient cohorts while reducing the influence of confounding variables. AI-powered cohort identification simplifies the process of selecting relevant patient groups for specific research or clinical purposes, leveraging complex and multi-modal data to uncover valuable insights.
Elucidata’s advanced data model supports the integration of electronic health records (EHR), genomic data, and clinical trial datasets. This approach allows researchers to map patient molecular profiles to both existing treatments and experimental therapies, improving the design and execution of clinical trials.
AI-ready data facilitates predictive modeling, tailored visualizations, and data-driven insights that empower clinicians to make more informed decisions. These tools enable the identification of high-risk patients, forecast disease progression, and recommend customized treatment strategies. Additionally, patient outcomes can be monitored across different cohorts, aiding in better resource allocation and improved clinical efficiency.
AI-ready data is changing research data workflows in the healthcare and biotechnology industry. As the volume and diversity of data continue to grow, the ability to integrate and analyze multi-modal datasets will be the differentiator for delivering personalized treatments and improving patient outcomes.
Elucidata offers scalable, secure, and innovative solutions for multi-modal data integration and is helping biopharma and healthcare organizations tackle their most complex challenges of data harmonization. With the ongoing developments in AI and machine learning, Elucidata will expand the capabilities of its platform, Polly, and ensure continued innovation in the field.
To learn more about Elucidata’s AI-ready data service, visit Elucidata | AI-readiness.
.svg)
.svg)
%201%20(1).svg)
%201%20(1).svg){kind=icon}
%20(1).svg){kind=avatar}
.webp)
.webp)
.svg)
%20(1).svg)
